Scholars Central

ArticlePublished 2010

Second Line Therapy for Advanced Pancreatic Adenocarcinoma: Where Are We and Where Are We Going? Highlights from the

Authors: Muhammad Wasif Saif, Christina Brus

Journal of the Pancreas

Volume 11 · Issue 4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Most patients with adenocarcinoma of the pancreas present with locally advanced or metastatic disease. Although single agent gemcitabine is widely accepted as first-line therapy, there is no current standard of care for gemcitabine-refractory patients. Common second-line chemotherapy regimens included oxaliplatin and 5-FU/leucovorin (OFF), gemcitabine and oxaliplatin (GEMOX), oxaliplatin and capecitabine (XELOX), and irinotecan-oxaliplatin. At the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, several new second-line chemotherapy regimens were presented, including gemcitabine and oxaliplatin with imatinib, single agent nab-paclitaxel, and the combination of high-dose capecitabine with oxaliplatin and sorafenib. These abstracts provide exciting new directions for the treatment of gemcitabine-refractory advanced pancreatic cancer

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of the Pancreas.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of the Pancreas
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Muhammad Wasif Saif”
  • BylineArticles whose byline prints “Christina Brus”